Hybrigenics runs its own drug discovery programs primarily in oncology, starting from target identification and validation all the way to proof of principle in animal models of human diseases, including screening of small molecules, lead optimization and preclinical evaluation of drug candidates

These programs are or will be partnered with pharmaceutical or biotechnology companies at various stages of research or development:
  > Apoptosis, a program focusing on BH3-domain proteins,
     already partnered with Laboratoires Servier,
  > Ubiquitin-regulated protein degradation pathway, a program
     focusing on Ubiquitin-Specific Proteases (USP) in oncology .

For more information on Hybrigenics’ programs, research platforms and partnering possibilities please contact: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it